SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001552781-14-000047
Filing Date
2014-01-29
Accepted
2014-01-29 12:48:47
Documents
9
Period of Report
2013-12-31

Document Format Files

Seq Description Document Type Size
1 NANOANTIBIOTICS 10Q nanoantibiotics_10q.htm 10-Q 373350
2 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002 exhibit_32-1.htm EX-32.1 5714
3 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 exhibit_31-1.htm EX-31.1 17630
  Complete submission text file 0001552781-14-000047.txt   1244480

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE nati-20131231.xml EX-101.INS 91529
5 XBRL SCHEMA FILE nati-20131231.xsd EX-101.SCH 17038
6 XBRL CALCULATION FILE nati-20131231_cal.xml EX-101.CAL 11136
7 XBRL DEFINITION FILE nati-20131231_def.xml EX-101.DEF 13017
8 XBRL LABEL FILE nati-20131231_lab.xml EX-101.LAB 80277
9 XBRL PRESENTATION FILE nati-20131231_pre.xml EX-101.PRE 56708
Mailing Address 9511 COLLINS AVENUE SUITE 807 SURFSIDE FL 33154
Business Address 9511 COLLINS AVENUE SUITE 807 SURFSIDE FL 33154 3055154118
NANOANTIBIOTICS, INC. (Filer) CIK: 0001580149 (see all company filings)

IRS No.: 462510769 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 333-190635 | Film No.: 14556014
SIC: 2834 Pharmaceutical Preparations